MARKET

EBS

EBS

Emergent Bio
NYSE

Real-time Quotes | Nasdaq Last Sale

92.31
+1.44
+1.58%
After Hours: 92.80 +0.49 +0.53% 17:37 03/05 EST
OPEN
92.60
PREV CLOSE
90.87
HIGH
92.99
LOW
86.16
VOLUME
726.43K
TURNOVER
--
52 WEEK HIGH
137.61
52 WEEK LOW
46.37
MARKET CAP
4.92B
P/E (TTM)
16.40
1D
5D
1M
3M
1Y
5Y
Emergent BioSolutions Capable Of Manufacturing 1B COVID-19 Vaccine Doses Annually, CEO Says
Emergent BioSolutions Inc (NYSE: EBS) has built the capacity to produce vaccines from AstraZeneca Plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ) around the clock, said CEO Bob Kramer on CNBC. “We are operating at a level where our capacity is well in ...
Benzinga · 3d ago
Emergent BioSolutions Turns Bearish, So Beware
TheStreet.com · 3d ago
Emergent BioSolutions says it can make 1 billion Covid vaccine doses annually
Emergent CEO Bob Kramer told CNBC that the company has infrastructure in place to produce Johnson & Johnson and AstraZeneca vaccines around the clock.
CNBC.com · 3d ago
Insider Trends: Emergent BioSolutions Insider Receives Shares Award Sells Portion for Taxes, Easing 90-Day Buy Trend
MT Newswires · 4d ago
Novavax taps Polish biotech firm Mabion for COVID-19 vaccine production
Mabion, a Polish biotechnology company has partnered with Novavax (NVAX) in a framework agreement that will pave the way for a potential manufacturing contract with the U.S.-based company for its COVID-19 vaccine
Seekingalpha · 4d ago
Insider Trends: Emergent BioSolutions Insider Awarded Shares Uses Portion to Pay Taxes, Scaling Down 90-Day Buy Trend
MT Newswires · 4d ago
Morning Bell With Jim Cramer: Buy Emergent BioSolutions
Jim Cramer shares stock-market news including approval of Johnson & Johnson's vaccine candidate, the upcoming jobs report, and the bond market vigilantes.
TheStreet.com · 5d ago
Emergent BioSolutions to Participate in Investor Conferences
GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following investor conferences: Jefferies Inaugural Global Plasma Summ...
GlobeNewswire · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EBS. Analyze the recent business situations of Emergent Bio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EBS stock price target is 118.50 with a high estimate of 144.00 and a low estimate of 86.00.
EPS
Institutional Holdings
Institutions: 505
Institutional Holdings: 48.89M
% Owned: 91.73%
Shares Outstanding: 53.30M
TypeInstitutionsShares
Increased
153
4.33M
New
111
-1.01M
Decreased
108
2.25M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
Fuad El-Hibri
Chairman/Director
Fuad El-Hibri El-Hibri
President/Chief Executive Officer/Director
Robert Kramer
Chief Financial Officer/Executive Vice President/Treasurer
Richard Lindahl
Chief Human Resource Officer/Executive Vice President
Katherine Strei
Executive Vice President/General Counsel/Secretary
Atul Saran
Executive Vice President
Adam Havey
Executive Vice President
Sean Kirk
Lead Director/Independent Director
Ronald Richard
Director
Seamus Mulligan
Director
Marvin White
Independent Director
Sue Bailey
Independent Director
Zsolt Harsanyi
Independent Director
Jerome Hauer
Independent Director
George Joulwan
Independent Director
Louis Sullivan
Independent Director
Kathryn Zoon
No Data
About EBS
Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).

Webull offers kinds of Emergent Biosolutions Inc stock information, including NYSE:EBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EBS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EBS stock methods without spending real money on the virtual paper trading platform.